science
FDA Panel Recommends XFG Variant for Fall Covid Shots
Replimune will submit an application to the FDA for the third time. Pfizer and Innovent Biologics reached a collaboration agreement valued at up to $10.5 billion.
May 29, 11:19 AM·1m read1 source
medpagetoday.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
The FDA's vaccine advisory panel recommended that fall Covid-19 shots target the XFG variant. Replimune will file a biologics license application with the FDA for the third time after two prior submissions. 5 billion in value.
Replimune plans to submit its application following earlier rejections by the agency. The company has not disclosed the specific product or indication under review.
The companies will work together on multiple drug candidates. 5 billion.
The panel's recommendation covers the composition of vaccines expected to be administered this fall. Health authorities will use the guidance to finalize strain selection for upcoming production.
Transparency
How sources framed this
Single source — no framing comparison available.
CorroborationModerate · 1 source
